RxDoctor Payments DataLook up a doctor →

Baptiste Marino, MD

General Practice · Matthews, NCNPI 1104070820

Payments from drug & device makers

$10,490in general payments, 2019–2025

Across 467 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Collegium Pharmaceutical, Inc.$1K
  • Pfizer$568
  • Idorsia Pharmaceuticals US Inc$372
  • Merck$310
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$10,42099%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,490 in reported general payments places this provider in the 95th percentile of 2,924 general practice providers in North Carolina.

See all general practice providers in North Carolina

Medicare billing

Part B allowed, 2024
$179,387
Medicare patients
177
Services billed
2,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl32$33,345
Xtampza ErOxycodone Myristate51$24,571
BelbucaBuprenorphine Hcl26$17,662
MovantikNaloxegol Oxalate39$15,680
Fentanyl51$6,223
BelsomraSuvorexant15$6,067
Oxycodone Hcl255$5,048
Naloxone Hcl61$4,015
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen135$3,761
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen138$2,719
Morphine Sulfate ErMorphine Sulfate67$1,721
Pregabalin41$775
Hydromorphone Hcl37$444
Gabapentin54$420
Tizanidine Hcl42$312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$1,182$42,23377 claims
Redhill Biopharma Inc.Movantik$87$15,68039 claims
MerckBelsomra$310$6,06715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,924 general practice providers in North Carolina.

Other general practice in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →